Marginal note:Definitions

• The following provision is not in force.

  1 (1) The following definitions apply in this Order.

  brand element

  brand element includes a brand name, trademark, trade name, logo, distinguishing guise, graphic arrangement, design or slogan that is reasonably associated with, or that evokes, a product, a service or a brand of product or service. (élément de marque)

  List

  List means the document entitled List of Nicotine Replacement Therapy Dosage Forms that may be Accessible for Self-selection by Purchasers or Consumers, as amended from time to time and published by the Government of Canada on its website. (Liste)

  nicotine replacement therapy

  nicotine replacement therapy means a natural health product, other than a homeopathic medicine, that

  • The following provision is not in force.

    (a) contains nicotine or its salts; and

  • The following provision is not in force.

    (b) is for administration in the oral cavity. (thérapie de remplacement de la nicotine)

  pharmacist

  pharmacist has the same meaning as in subsection C.01.001(1) of the Food and Drug Regulations. (pharmacien)

  Regulations

  Regulations means the Natural Health Products Regulations. (Règlement)

  young person

  young person means an individual who is under 18 years of age. (jeune)

• The following provision is not in force.

  Marginal note:Words and expressions

  (2) Unless the context otherwise requires, words and expressions used in this Order have the same meaning as in the Regulations.

Marginal note:Application of Regulations

• The following provision is not in force.

  2 (1) For greater certainty, unless otherwise provided by this Order, the Regulations apply to a nicotine replacement therapy referred to in this Order, with the following modifications:

  • The following provision is not in force.

    (a) in paragraphs 18(1)(a) and 39(1)(a), section 92 and subsection 103.4(1) of the Regulations, the reference to “these Regulations” is to be read as including a reference to this Order; and

  • The following provision is not in force.

    (b) in paragraphs 17(1)(e) and (2)(d) of the Regulations, the reference to “Part 5” is to be read as including a reference to this Order.

• The following provision is not in force.

  Marginal note:Non-application — clinical trials

  (2) This Order does not apply to the sale or importation of a nicotine replacement therapy for the purposes of a clinical trial regulated by Part 4 of the Regulations.

Marginal note:Application for product licence

3 An application for a product licence, in respect of a nicotine replacement therapy, that is submitted under section 5 of the Regulations must contain, in addition to the information and documents required under that section, mock-ups of every label to be used in connection with the nicotine replacement therapy — including any leaflet, any package insert and any information that appears on a website — and mock-ups of its packages.

Marginal note:Application for amendment

4 An application to amend a product licence, in respect of a nicotine replacement therapy, that is submitted under subsection 11(2) of the Regulations must contain, in addition to the information and documents required under that subsection, mock-ups of every label to be used in connection with the nicotine replacement therapy — including any leaflet, any package insert and any information that appears on a website — and mock-ups of its packages, to be used in conjunction with it after the change, if the change is any of those described in paragraphs 11(1)(a) to (h) of the Regulations or in section 5.

Marginal note:Changes — brand name or non-medicinal ingredient

5 Despite section 12 of the Regulations, if a licensee makes any of the following changes in respect of a nicotine replacement therapy, the licensee must not sell any lot or batch of the nicotine replacement therapy affected by the change unless an application to amend the product licence is submitted in accordance with subsection 11(2) of the Regulations and the licence is amended accordingly:

• The following provision is not in force.

  (a) a change to a brand name that was submitted under paragraph 5(e) of the Regulations; or

• The following provision is not in force.

  (b) an addition or substitution of a non-medicinal ingredient that affects the flavour of the nicotine replacement therapy but that does not affect its safety or efficacy.

Marginal note:Issuance and amendment

6 For the purposes of sections 7 and 10 of the Regulations, in respect of a nicotine replacement therapy, the application for a product licence or the application to amend a product licence must also be in accordance with section 3 or 4, as the case may be.

Marginal note:Sale on retail basis

• The following provision is not in force.

  7 (1) A person must not sell a nicotine replacement therapy on a retail basis unless it is in a dosage form set out in the List.

• The following provision is not in force.

  Marginal note:Exception

  (2) Subsection (1) does not apply to a pharmacist or a person working under their supervision who sells a nicotine replacement therapy on a retail basis if the nicotine replacement therapy is not otherwise accessible to the public for self-selection.

Marginal note:Sale for further sale

8 A person must not sell a nicotine replacement therapy that is in a dosage form not set out in the List to another person, other than a pharmacist, for further sale on a retail basis by that other person.

Marginal note:Brand name

9 A person must not sell a nicotine replacement therapy under a brand name for which there are reasonable grounds to believe may

• The following provision is not in force.

  (a) mislead a purchaser or consumer in respect of the intended use of the nicotine replacement therapy;

• The following provision is not in force.

  (b) be appealing to young persons;

• The following provision is not in force.

  (c) be associated with young persons; or

• The following provision is not in force.

  (d) be mistaken for cannabis as defined in subsection 2(1) of the Cannabis Act or for a food.

Marginal note:Appealing to young persons

10 A person must not sell a nicotine replacement therapy if its label or package displays statements or graphic design elements, including brand elements, for which there are reasonable grounds to believe that they could be appealing to young persons.

Marginal note:Flavours

11 A person must not manufacture or sell a nicotine replacement therapy that is in a dosage form set out in the List if it contains the flavour of a confectionery, dessert, soft drink or energy drink.

Marginal note:Flavours — mint or menthol

12 A person must not manufacture or sell a nicotine replacement therapy that is in a dosage form not set out in the List if it contains a flavour other than mint, menthol or a combination of mint and menthol.

Marginal note:Labelling

• The following provision is not in force.

  13 (1) A person must not sell a nicotine replacement therapy unless it is labelled in accordance with this Order.

• The following provision is not in force.

  Marginal note:Exception

  (2) Despite subsection (1), a person may sell a nicotine replacement therapy that is not labelled in accordance with this Order if the sale is to a manufacturer or distributor.

Marginal note:Statement

14 A statement, in both official languages, indicating an intended use by individuals 18 years of age or older must be shown on the outer label of a nicotine replacement therapy or, if there is no outer label, on the inner label.

Marginal note:Warnings

15 The warnings “WARNING: Nicotine is highly addictive.” and “AVERTISSEMENT : La nicotine crée une forte dépendance.” must be shown on the principal display panel of the inner label of a nicotine replacement therapy and, if there is an outer label, on the principal display panel of the outer label.

Marginal note:Presentation — statements and warnings

• The following provision is not in force.

  16 (1) The statements and warnings required under sections 14 and 15 must be

  • The following provision is not in force.

    (a) clearly and prominently displayed; and

  • The following provision is not in force.

    (b) readily discernible to a purchaser or consumer under the customary conditions of purchase and use, without having to manipulate the label.

• The following provision is not in force.

  Marginal note:Presentation — warnings

  (2) The warnings required under section 15 must be

  • The following provision is not in force.

    (a) in characters of a single colour of type that is a visual equivalent of 100% solid black type on a white background or a uniform neutral background with maximum 5% tint of colour;

  • The following provision is not in force.

    (b) in characters of a standard sans serif font that is not decorative; and

  • The following provision is not in force.

    (c) in characters of a type size of at least 6 points.

Marginal note:Interpretation — advertisement

17 For the purposes of sections 18, 19, 24 and 25, advertisement as defined in section 2 of the Food and Drugs Act, does not include advertising by means of the label or package of the nicotine replacement therapy.

Marginal note:Smoking cessation

18 A person must not advertise or otherwise promote a nicotine replacement therapy for a use that is other than smoking cessation.

Marginal note:Appealing to young persons

19 A person must not advertise or otherwise promote a nicotine replacement therapy if there are reasonable grounds to believe that the advertisement or promotion could be appealing to young persons.

Marginal note:Flavours

20 A person must not advertise a nicotine replacement therapy, including by means of its label or package, in a manner that could cause a purchaser or consumer to believe that it contains

• The following provision is not in force.

  (a) if the nicotine replacement therapy is in a dosage form set out in the List, the flavour of a confectionery, dessert, soft drink or energy drink; or

• The following provision is not in force.

  (b) if the nicotine replacement therapy is in a dosage form not set out in the List, a flavour other than mint, menthol or a combination of mint and menthol.

Marginal note:Flavour name — descriptive or qualifying words

21 A person must not advertise a nicotine replacement therapy, including by means of its label or package, by displaying a flavour name that is preceded or followed by any descriptive or qualifying words.

Marginal note:Flavour name — reasonably conveyed

22 A person must not advertise a nicotine replacement therapy that is in a dosage form set out in the List, including by means of its label or package, by displaying a flavour name that does not reasonably convey its flavour.

Marginal note:Flavour name — mint or menthol

23 A person must not advertise a nicotine replacement therapy that is in a dosage form not set out in the List, including by means of its label or package, by displaying a flavour name that is other than “mint”, “menthol” or a combination of “mint” and “menthol”.

Marginal note:Statements

24 Any advertisement for a nicotine replacement therapy must contain

• The following provision is not in force.

  (a) in the case of an advertisement in English, the statement

  • (i) “This product is intended for smoking cessation only. Do not use if you are under 18 years of age.”, or

  • (ii) “Only to be used by adults who are trying to quit smoking.”;

• The following provision is not in force.

  (b) in the case of an advertisement in French, the statement

  • (i) “Ce produit est uniquement destiné à vous aider à cesser de fumer. Ne pas utiliser si vous avez moins de 18 ans.”, or

  • (ii) “À utiliser uniquement par des adultes qui désirent cesser de fumer.”;

• The following provision is not in force.

  (c) in the case of an advertisement in both official languages, the statements set out in

  • (i) subparagraphs (a)(i) and (b)(i), or

  • (ii) subparagraphs (a)(ii) and (b)(ii); and

• The following provision is not in force.

  (d) in any other case, the statement set out in subparagraph (a)(i) or (ii) or (b)(i) or (ii).

Marginal note:Warnings

25 Any advertisement for a nicotine replacement therapy must contain

• The following provision is not in force.

  (a) in the case of an advertisement in English, the warning “WARNING: This product contains nicotine. Nicotine is highly addictive.”;

• The following provision is not in force.

  (b) in the case of an advertisement in French, the warning “AVERTISSEMENT : Ce produit contient de la nicotine. La nicotine crée une forte dépendance.”;

• The following provision is not in force.

  (c) in the case of an advertisement in both official languages, the warnings set out in paragraphs (a) and (b); and

• The following provision is not in force.

  (d) in any other case, the warning set out in paragraph (a) or (b).

Marginal note:Audio advertising

26 The statements and warnings required under sections 24 and 25 that are contained in an audio advertisement for a nicotine replacement therapy must be communicated

• The following provision is not in force.

  (a) in their entirety at the same speed, volume and tone as the main message, without any word being emphasized more than any other; and

• The following provision is not in force.

  (b) without any music or background sound.

Marginal note:Visual advertising

27 The statements and warnings required under sections 24 and 25 that are contained in a visual advertisement for a nicotine replacement therapy must be

• The following provision is not in force.

  (a) clearly and prominently displayed; and

• The following provision is not in force.

  (b) readily discernible to a purchaser or consumer.

Marginal note:Audio-visual advertising

28 Sections 26 and 27 apply to an advertisement for a nicotine replacement therapy that consists of both audio and visual components.

Marginal note:Six month transition — appealing to young persons

• The following provision is not in force.

  29 (1) A person may sell a nicotine replacement therapy that is not in accordance with section 10 during the period of six months after the day on which this Order comes into force.

• The following provision is not in force.

  Marginal note:Six month transition — labelling

  (2) A person may sell a nicotine replacement therapy that is not labelled in accordance with sections 14 to 16 during the period of six months after the day on which this Order comes into force.

• The following provision is not in force.

  Marginal note:Six month transition — advertising

  (3) A person may advertise a nicotine replacement therapy in a manner that is not in accordance with sections 18 to 28 during the period of six months after the day on which this Order comes into force.

Marginal note:Permitted sale — appealing to young persons

• The following provision is not in force.

  30 (1) A person may sell a nicotine replacement therapy that is not in accordance with section 10 if it was labelled before the day on which this Order comes into force or, in the case of a nicotine replacement therapy that was imported, it was imported and labelled in accordance with the Regulations before that day.

• The following provision is not in force.

  Marginal note:Permitted sale — labelling

  (2) A person may sell a nicotine replacement therapy that is not labelled in accordance with sections 14 to 16 if it was labelled before the day on which this Order comes into force or, in the case of a nicotine replacement therapy that was imported, it was imported and labelled in accordance with the Regulations before that day.

• The following provision is not in force.

  Marginal note:Permitted sale — advertising

  (3) A person may sell a nicotine replacement therapy that, by means of its label or package, is not advertised in accordance with sections 20 to 23 if it was labelled before the day on which this Order comes into force or, in the case of a nicotine replacement therapy that was imported, it was imported and labelled in accordance with the Regulations before that day.